Can nanotechnology help immunotherapy in glioblastoma multiforme? Tumor protein loaded nanoparticles

Glioblastoma multiforme is the most frequent primary brain tumor that despite current treatment has a dismal prognosis. Therefore a lot of effort is put in adjuvant therapies with one possibility using dendritic cells (DCs) to harness the immune system. This DC immunotherapy consists of autologous DCs ex vivo loaded with autologous tumor lysate. But the requirement for autologous cell cultures causes this therapy to be labor intensive and expensive. We believe nanoparticles (NPs) can circumvent this problem. Preclinical studies have already shown that NPs of a specific size can efficiently be taken up by DCs and…